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IMPORTANCE Patients with attention-deficit/hyperactivity disorder (ADHD) are at an
increased risk of attempting suicide. Stimulants, such as methylphenidate hydrochloride, are
themost common treatment for ADHD, but the association between their therapeutic use
and suicide is unclear.
OBJECTIVE To investigate the association betweenmethylphenidate and the risk of suicide
attempts.
DESIGN, SETTING, AND PARTICIPANTS A population-based, electronicmedical records
database from the Hong Kong Clinical Data Analysis & Reporting Systemwas used to identify
25 629 individuals aged 6 to 25 years who were treated with methylphenidate between
January 1, 2001, and December 31, 2015. Those who had attempted suicide were included in
the analysis. A self-controlled case series design was used to control for time-invariant
characteristics of the patients.
MAIN OUTCOMES ANDMEASURES Relative incidence of suicide attempt during periods when
patients were exposed tomethylphenidate compared with nonexposed periods.
RESULTS Among 25 629 patients with methylphenidate prescriptions, 154 had their first
recorded suicide attempt within the study period; of these individuals, 111 (72.1%) were male;
mean (SD) age at baseline was 7.15 (2.19) years. The overall incidence of suicide attempts
during methylphenidate treatment was 9.27 per 10000 patient-years. An increased risk of
suicide attempts was detected during the 90-day period before methylphenidate was
initiated, with an incidence rate ratio (IRR) of 6.55 (95% CI, 3.37-12.72). The IRR remained
elevated during the first 90 days of treatment (IRR, 3.91; 95% CI, 1.62-9.42) before returning
to baseline levels during ongoing treatment (IRR, 1.35; 95% CI, 0.77-2.38). When the risk
during the first 90 days of treatment was compared with the 90 days preceding first
treatment, the incidence of suicide attempts was not elevated (IRR, 0.78; 95% CI, 0.26-2.35).
CONCLUSIONS AND RELEVANCE The incidence of suicide attempts was higher in the period
immediately before the start of methylphenidate treatment. The risk remained elevated
immediately after the start of methylphenidate treatment and returned to baseline levels
during continuation of methylphenidate treatment. The observed higher risk of suicide
attempts before treatment may reflect emerging psychiatric symptoms that trigger medical
consultations that result in a decision to begin ADHD treatment. Therefore, this study’s
results do not support a causal association betweenmethylphenidate treatment and suicide
attempts.
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A ttention-deficit/hyperactivitydisorder (ADHD) isacom-mon neurodevelopmental disorder in children, withworldwideprevalence rates in school-agedchildrenes-
timatedat 5%to7%.1,2 InHongKong (HK), the reportedpreva-
lence ofADHD is estimated to be6.1% in schoolboys and 3.9%
in early adolescents.3,4 Attention-deficit/hyperactivity disor-
der is associatedwith adiverse range ofmental health comor-
bidities and adverse health, academic, and psychosocial
outcomes.5-8 Individuals with ADHD are at increased risk of
both attempted and completed suicide, even if comorbidpsy-
chiatric disorders are clinically treated.9
National guidelines recommend psychostimulant medi-
cation for the treatment of ADHD.10-12 During the past 2 de-
cades, the rate of medication use for ADHD has risen rapidly
worldwide.13-18 TheprevalenceofADHDmedicationuse inHK
is approximately 1% in school-aged children and adolescents
and has increased 14-fold over the past decade.18Methylphe-
nidate hydrochloride, in particular, is commonly used as the
first-line therapy. In 2009, the European Medicines Agency
conducted a review of the safety ofmethylphenidate. The re-
view concluded that further research on the association be-
tween methylphenidate and psychiatric adverse effects, in-
cluding suicide risk, was needed.19
Although there has been some concern about a potential
association between methylphenidate and suicide-related
events,20 few studies have addressed this issue directly. One
Swedish register-based study investigated the risk of suicidal
behavior among individuals receiving methylphenidate and
other stimulants.21 When comparing treated and nontreated
patients with ADHD, this study found that methylphenidate
or other stimulant use was associated with a 31% increase in
the rate of suicide-related events.21However, this analysis did
not adjust for potential confounding factors that may ac-
count for this association. For instance, a recent study on sui-
cide in school-aged children and adolescents showed that
ADHDwasoverrepresented insuicidevictims.22Previousstud-
ies have also suggested that comorbid disorders and familial/
social factors may all play important roles in the association
betweenADHDandsuicide.9,23-25 Ina follow-upanalysis in the
abovementioned register study,whenperiodswith andwith-
out treatmentwere comparedwithin the samepatient, no in-
creased risk of suicide-related events during the treatment
periods was found.21 Therefore, at present, there is still
uncertainty around the potential effects of methylphenidate
on the suicidal behavior of patients. Hence, the aim of the
present study was to examine the association between
methylphenidate and the risk of suicide attempts.
Methods
Data Source
This studyuseddata from theClinicalDataAnalysis&Report-
ing System (CDARS), an electronic health record database de-
veloped by the HK Hospital Authority, a statutory body that
managesallpublichospitalsandtheirambulatoryclinics inHK.
The service is available to all HK residents (>7.3 million) and
covers approximately 80%of all hospital admissions inHK.26
Data fromCDARShavebeenvalidated andused for various in-
vestigations ofmedication safety.26-33 Patient-specific data in
CDARS include diagnosis, prescription, information on hos-
pital admissions and discharges, payment method, and pre-
scription and dispensing information.34 CDARS contains in-
patient, outpatient, and emergency department admissions
records, anonymized to protect patient confidentiality. The
studyprotocolwas approvedby the institutional reviewboard
of theUniversity ofHongKong/Hospital AuthorityHongKong
West Cluster.
Self-controlled Case Series Design
We used the self-controlled case series (SCCS)35 study design
to investigate the association between methylphenidate and
suicide attempts. In this design, used previously to investi-
gate the effects ofmethylphenidate on trauma and psychosis
risk,30,31 patients serve as their own control.36 The SCCS de-
sign relies on within-person comparisons in a population of
individuals who have experienced both the outcome and ex-
posureof interest.36 Incidence rate ratios (IRRs) arederivedby
comparing the rate of events duringperiods ofmedication ex-
posurewith the rateduringall otherobserved timeperiods (ie,
withoutmedication).Amajoradvantageof thisdesignover the
classic design is that it controls for potential effects of mea-
sured and unmeasured time-invariant confounders that vary
between individuals (ie, genetic factors, disease severity, and
socioeconomic factors). Furthermore, we adjusted for time-
varying factors, such as age and season, which are known to
affect methylphenidate treatment prescribing.37,38 In addi-
tion to the standard SCCS analysis, the nonparametric SCCS
approach was applied to investigate risk changes during the
observation period.39,40
Case Identification
Individuals aged6 to 25yearswho received at least 1 prescrip-
tion formethylphenidate andwhohadmade at least 1 suicide
attempt during the study period (January 1, 2001, to Decem-
ber 31, 2015) were identified in CDARS. The suicide attempt
codes were identified through the International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) diagnostic codes E950 to E959.41 The statistical model-
ing of the SCCS analysis requires incident cases to fulfill the
Key Points
Question Is treatment with methylphenidate associated with an
increased risk of suicide attempts?
Findings In this population-based, case series study of 154
patients with a suicide attempt identified from 25 629 patients
who were receiving methylphenidate for treatment of
attention-deficit/hyperactivity disorder, the risk of suicide
attempts was 6.5-fold higher during the 90-day period before
methylphenidate was initiated, remained elevated 4-fold during
the first 90 days of treatment, and returned to baseline levels
during ongoing treatment.
Meaning The increased risk of suicide attempts preceding the
initiation of methylphenidate is not causally related to the drug’s
effects.
Research Original Investigation Risk of Suicidal EventsWith Methylphenidate Treatment
E2 JAMAPsychiatry Published online July 26, 2017 (Reprinted) jamapsychiatry.com
© 2017 American Medical Association. All rights reserved.
Downloaded From: http://jamanetwork.com/ by a University of Dundee User  on 08/14/2017
model assumption36; therefore, patientswhohadmade a sui-
cide attempt before the study period were excluded. Only
methylphenidate and atomoxetine are licensed for the treat-
ment ofADHD inHK; therefore, the observationperiodswere
censoredbyatomoxetine treatment toavoidcoprescribingsitu-
ations that could affect comparisons.
We commenced follow-up at age 6 years, as methylphe-
nidate is not recommended for younger children.42 There has
been an increasing trend of methylphenidate use in college-
aged young adults up to age 25 years.43 Observation periods
began on January 1, 2001, or the sixth birthday of the patient
(whichever was later) and ended on December 31, 2015, the
26th birthday of the patient, date of receiving atomoxetine
treatment, or date of registered death (whichever was ear-
lier). Because the aim of this study was to investigate the as-
sociation betweenmethylphenidate and suicide attempts, all
methylphenidate users, regardless of the presence of a for-
mal diagnosis of ADHD, were included.
Exposures andOutcomes
For each included participant, all methylphenidate prescrip-
tions and suicide attempts were identified. All methylpheni-
date formulations (standard and extended release) and all
strengthswere included in theanalysis. Exposedperiodswere
defined as time receiving medication, with the duration be-
tween prescription start and enddates recorded in CDARS for
eachprescription.More than99%of theprescriptionshad the
intended start and enddates as recorded in our data set. Daily
dosages and the quantity prescribed were used to determine
the duration of treatment if the prescription enddatewas not
available. Median values for exposure duration were im-
puted when the above information was missing. We divided
patient time into4discrete categories: absenceofmethylphe-
nidate (baseline period, including patient-timebefore and af-
termethylphenidate exposure), 90daysbefore the firstmeth-
ylphenidate exposure (pre-exposure period), first 90 days of
methylphenidate use, and subsequentmethylphenidate use.
Wedidnotassumethatparticipants receivedcontinuous treat-
menton initiationofmethylphenidate, becausecliniciansmay
offer drugholidays to patientswithADHDduring school holi-
days and treatment may be stopped and started for various
other reasons.30,31 Thepre-exposureperiodwasdefinedas the
timebefore the firstmethylphenidateprescription; thus, there
were no pre-exposure periods before the second or subse-
quentmethylphenidate treatments.Thestudydesignandtime-
line for a single hypothetical participant are given in Figure 1.
The corresponding date of a suicide attemptwas identified as
an event date, and only the first recorded suicide attempt for
each patient was included in the analysis. In SCCS designs,
there shouldbenocensoringby theoutcomeof interest, as this
would violate their assumption and invalidate the results.36
Weconducted avalidation analysis by reviewing the informa-
tion in CDARS. Through doing this, we identified that, in 153
of 154 (99.4%) cases, the ICD-9-CM diagnosis code of a sui-
cideattemptwasconfirmed in themedical recordsbyanemer-
gencydepartment clinician, hospital pediatrician, and/or psy-
chiatrist. Consequently, the risk of misclassification is
considered to be low.
Statistical Analysis
Theassociationbetweenmethylphenidate treatment and sui-
cide attempts was calculated by comparing the rate of sui-
cide attempts during exposure periodswith that during base-
lineperiods.Adjusted IRRandthecorresponding95%CIswere
calculated using conditional Poisson regression, adjusted for
age in 1-year bands and season. A 90-day pre-exposure pe-
riod was added to take account of the possibility that the sui-
cide attempt may affect the likelihood of methylphenidate
treatment, which in turn may introduce bias into the risk es-
timate during treatment. We separated the first 90 days of
methylphenidate use to allow the detection of any tempo-
rary change in the IRR of suicide attempts, and we also com-
pared the rate of suicide attempts between the pre-exposure
period and the methylphenidate-exposed periods. To inves-
tigate whether emergent psychiatric disorders could lead to
methylphenidate treatment, post hoc analyses were con-
ducted, using the same setting as the original analysis, to test
theassociationbetweenmethylphenidate treatmentandother
psychiatric conditions (ICD-9-CM codes 290-319). A signifi-
cance level of 5%wasused in all statistical analyses. SAS, ver-
sion 9.4 (SAS Institute Inc) and R, version 3.3.1 (http://www
.R-project.org)were used for datamanipulation and analysis.
Sensitivity Analyses
Sensitivity analyses were planned to test the validity and ro-
bustness of the initial study results. These analyses tested the
Figure 1. Illustration of Self-controlled Case Series Study Design
Baseline period (no drug exposure)
90-d Period before first methylphenidate use
First 90 d of methylphenidate treatment
With methylphenidate treatment
Start of
observation
period
First
methylphenidate
prescription
End of
methylphenidate
treatment
Start of further
methylphenidate
treatment
End of
observation
period
Suicide attempta
a Event can take place any time
throughout the observation period;
no censoring on the event date.
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effects of (1) different drug nonadherence scenarios;
(2) restricting the sample to a 6-month age band; (3) more
than 10weeksofmethylphenidate exposure; (4) removingpa-
tients with a diagnosis of substance misuse/dependence;
(5) restricting observation periods to the date of prescription
of any antidepressant or antipsychotic medications;
(6) removing patients where the event occurred on the first
day of prescription; (7) redefining the observation period to
January 1, 2001, the sixth birthday of the patient, the first ob-
served date of ADHD diagnosis, or the first date of methyl-
phenidate treatment, whichever occurred last; and
(8) restricting to incident patients receiving methylpheni-
date. The details of these variables can be found in eAppen-
dix 1 in the Supplement.
Results
Among 25629 patients with methylphenidate prescriptions,
19 had attempted suicide before the observation period and
were therefore removed fromtheanalysis, asperprotocol.One
hundred fifty-four patients had their first recorded suicide at-
temptwithin the observation period (eFigure 1 in the Supple-
ment); of these, 111 (72.1%)weremale and 43 (27.9%)were fe-
male.Themean (SD)ageat commencementofobservationwas
7.15 (2.19) years (range, 6.0-16.47 years), and the mean dura-
tion of follow-up per participant was 12.15 (2.82) years. Mean
methylphenidate exposure was 2.22 (2.33) years per partici-
pant. Themedian length of eachprescriptionwas 70days (in-
terquartile range [IQR], 35-105 days; range, 1-1023 days), and
3617 of 4300 (84.1%) of the prescriptions were for short-
acting methylphenidate. Of 154 patients, 112 (72.7%) had an
ADHD diagnosis, and the median age at diagnosis was 10.4
years (IQR, 8.3-13.4 years). Seventy-two (46.8%) patients had
at least 1 prescription for an antidepressant or antipsychotic
during the study period; 17 began receiving an antidepres-
sant or antipsychotic before their firstmethylphenidate treat-
ment, and 55 patients started after initiation ofmethylpheni-
date. Broader psychiatric comorbidities for these patients are
reported in eTable 1 in the Supplement. Amongpatientswith-
out an ADHD diagnosis, 39 of 42 (92.9%) had at least 1 other
psychiatric diagnosis (ICD-9-CM codes 290-319); 16 of 42
(38.1%) of these had a diagnosis of autism spectrum disorder
(eTable 2 in the Supplement). Of the 154 suicide attempts, 44
occurred during methylphenidate treatment and 110 oc-
curred during the off-treatment period (Table 1). Themedian
ageof the indexsuicideattemptgroupwas15.4years (IQR, 12.7-
18.1 years) (eFigure 2 in the Supplement). The overall inci-
dence of suicide attempts during methylphenidate treat-
mentwas 9.27 per 10000 patient-years. The crude incidence
of suicide attempts in the different risk windows is summa-
rized in Table 2. No participants in the SCCS died of com-
pleted suicide during the study period.
The analysis indicated some association between the
decision to start methylphenidate treatment and suicide
attempts (Table 3). After age and seasonwere adjusted, an in-
creased risk of suicide attempts was detected during the 90-
day period beforemethylphenidate initiation (IRR, 6.55; 95%
CI, 3.37-12.72). The IRR remained elevated during the first 90
days of methylphenidate treatment (IRR, 3.91; 95% CI, 1.62-
9.42) before returning to baseline levels during prolonged
treatment (IRR, 1.35;95%CI,0.77-2.38) (Table3).Adirect com-
parison between the risk of suicide attempts during the pre-
exposure period and the methylphenidate treatment period
showed that the corresponding riskwas not increased during
the first90daysofmethylphenidate treatment (IRR,0.78;95%
CI,0.26-2.35).However, a 72%lower riskwas found in the sub-
sequentperiodofmethylphenidate treatment (IRR,0.28; 95%
CI, 0.08-0.94) compared with the pre-exposure period. Fur-
ther analysis usingnonparametric, spline-basedSCCS showed
that the risk of suicide attempts increased significantly be-
fore the initiation ofmethylphenidate treatment and reached
a peak within 100 days before methylphenidate treatment
(Figure 2). The age- and sex-stratified results showed a simi-
lar pattern to the overall analysis (eTable 3 in the Supple-
ment). Post hoc analysis revealed that an increased risk of any
Table 2. Incidence of Suicide Attempts AmongMethylphenidate Users in Different RiskWindows
Risk Window No. of Events Patient-years Incidence Per 10 000 Patient-years (95% CI)
Before prerisk 19 65 362 2.91 (1.86-4.54)
90 d Before first methylphenidate treatment 12 5594 21.45 (12.28-37.46)
First 90 d of methylphenidate treatment 6 4687 12.80 (5.87-27.90)
Subsequent methylphenidate treatment 36 42 728 8.43 (6.09-11.66)
After methylphenidate treatment 81 68 636 11.80 (9.50-14.66)
Table 1. Patient Characteristics
Characteristic
No. of
Patients (%)
Age at Baseline,
Mean (SD), y
Dose, Median
(Range) [IQR],
mg/d
Length of Prescription,
Median (Range) [IQR], d
Exposed Period Unexposed Period
Events,
No.
Total
Follow-up
Time,
Patient-years
Events,
No.
Total
Follow-up
Time,
Patient-years
All 154 (100) 7.15 (2.19) 20 (2.5-60) [15-35] 70 (1-1023) [35-105] 44 342.1 110 1529.6
Male 111 (72.1) 7.13 (2.05) 20 (2.5-60) [15-35] 71 (1-838) [42-107] 32 265.4 79 1085.4
Female 43 (27.9) 7.20 (2.54) 20 (5-60) [15-35] 56 (1-1023) [28-96] 12 76.7 31 444.2
Abbreviation: IQR, interquartile range.
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psychiatricdisorderwasdetectedduring the90-dayperiodbe-
fore methylphenidate initiation (IRR, 22.14; 95% CI, 21.31-
22.99). The risk remained elevated during the first 90 days of
methylphenidate treatment (IRR,9.40;95%CI,8.94-9.88) and
during prolonged treatment (IRR, 1.53; 95% CI, 1.44-1.62)
(eTable4 in theSupplement). Theadditional sensitivity analy-
ses did not change this general picture of results (eFigures 3-5
in the Supplement and Table 3).
Discussion
In this population-based, retrospective study, the incidenceof
methylphenidate-relatedsuicideattemptsdemonstrateda6.5-
foldand4-foldelevationduring the90-dayperiodsbefore and
after the start of treatment, respectively. This finding sug-
gests that thedecision to startmethylphenidate treatment fol-
lows the period of increasing risk for suicide attempts, with
the risk remainingelevatedand thenbeginning to fall after ini-
tiation ofmethylphenidate. Themost parsimonious interpre-
tation of this pattern of temporal association is that the ob-
served increased risk of suicide attempts is not due to
methylphenidate but precedes it, perhaps reflecting changes
in behavioral andmental health symptoms or associated im-
pairment that leadtoamedical consultation,which in turnmay
contribute to thedecision toprescribemethylphenidate. This
hypothesis fits with the finding that the incidence of suicide
attempts just after treatment initiationwas comparable to that
just before it, while after more than 90 days of methylpheni-
date use, the incidence was similar to that during the base-
lineperiod. Inaddition, thespline-basedSCCSanalysis showed
adecreasing incidence of suicide attempts on the initiation of
methylphenidate treatment. However, our results cannot be
interpretedasdemonstrating thatmethylphenidatehasan im-
mediate effect on lowering the risk of suicide attempts. The
increased risk of suicide attempts before treatmentmay have
been missed in a classic cohort study in which patients with
Table 3. Results From the Self-Controlled Case Series Analyses
Risk Window Adjusted IRR (95% CI)
P
Value
Suicide Attempt (n = 154)
90 d Before 1st methylphenidate
treatment
6.55 (3.37-12.72) <.01
First 90 d with methylphenidate
treatment
3.91 (1.62-9.42) <.01
Subsequent methylphenidate treatment 1.35 (0.77-2.38) .30
Sensitivity Analyses
6-mo Age band (n = 154)
90 d Before 1st methylphenidate
treatment
5.36 (2.81-10.23) <.01
First 90 d with methylphenidate
treatment
4.04 (1.87-8.75) <.01
Subsequent methylphenidate
treatment
1.44 (0.88-2.36) .15
Patients with >10 wk methylphenidate
exposure (n = 113)
90 d Before 1st methylphenidate
treatment
5.05 (2.04-12.48) <.01
First 90 d with methylphenidate
treatment
3.38 (1.15-9.89) .03
Subsequent methylphenidate
treatment
1.38 (0.77-2.46) .28
Censor by antidepressants/antipsychotics
(n = 154)
90 d Before 1st methylphenidate
treatment
8.08 (3.88-16.85) <.01
First 90 d with methylphenidate
treatment
5.79 (2.28-14.73) <.01
Subsequent methylphenidate
treatment
1.14 (0.56-2.33) .72
Remove patients with substance
dependence (n = 114)
90 d Before 1st methylphenidate
treatment
6.91 (3.44-13.87) <.01
First 90 d with methylphenidate
treatment
3.69 (1.42-9.6) <.01
Subsequent methylphenidate
treatment
1.42 (0.77-2.61) .26
Remove cases with event on the 1st day of
treatment (n = 137)
90 d Before 1st methylphenidate
treatment
5.54 (2.72-11.29) <.01
First 90 d with methylphenidate
treatment
3.76 (1.56-9.05) <.01
Subsequent methylphenidate
treatment
1.32 (0.75-2.33) .33
Start of observation at January 1, 2001;
the 6th birthday of the patient; the first
observed date of ADHD diagnosis; or first
date of methylphenidate treatment,
whichever occurred last (n = 126)
90 d Before 1st methylphenidate
treatment
7.28 (3.22-16.5) <.01
First 90 d with methylphenidate
treatment
3.65 (1.45-9.18) <.01
Subsequent methylphenidate
treatment
1.25 (0.69-2.28) .46
Incident methylphenidate users only
(n = 140)
90 d Before 1st methylphenidate
treatment
6.57 (3.37-12.8) <.01
First 90 d with methylphenidate
treatment
4.02 (1.66-9.73) <.01
Subsequent methylphenidate
treatment
1.32 (0.73-2.4) .36
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; IRR, incidence
rate ratio.
Figure 2. Results From the Spline-Based Self-controlled Case
Series Analysis
20
15
10
5
0
–400 –300 –200 –100 400300200100
In
ci
de
nc
e 
Ra
te
 R
at
io
Time Since Exposure, d
0
Incidence rate ratio (IRR) of suicide attempts throughout the time before and
after methylphenidate exposure. The solid line is the estimated IRR, the dashed
lines indicate the 95% CI, and the blue dashed line indicates baseline IRR.
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either events or exposures before the commencement of the
study are usually excluded. To our knowledge, this is the first
study investigating the risk of suicide attempts before and af-
ter the start ofmethylphenidate treatment. The study results
thus provide new evidencewithwhich to interpret reports of
an elevated risk of suicide attempts after initiation of meth-
ylphenidate treatment.
Several factorsmay explain why the initiation ofmethyl-
phenidate treatment tends to coincide with the times of in-
creased risk of suicide attempts. The initiation of new medi-
cationoftenoccursata timeofspecificconcernsaboutpatients’
health. Patients with ADHD are at higher risk of suicide-
relatedevents.9,21,44Thedecision tostart treatmentwithmeth-
ylphenidatemaybe a response to changes in behavioral or re-
latedpsychiatric problems.Theseproblemscouldbe transient
psychiatric disorderswithADHDor clinical observation in the
period leading to initiation ofmethylphenidate. It is alsowell
recognized that patients with ADHD are prone to cognitive,
emotional, and behavioral comorbidities, for example, de-
pression or disruptive behavioral disorders.8 These comor-
biditiesmay increase the likelihoodof suicideattempts,which
mayconsequently increaseboth the likelihoodofmedical and
psychiatric consultationsandreceivingamethylphenidatepre-
scription. This position is further supported by the post hoc
analysis that found an increased risk of other psychiatric dis-
ordersbeforemethylphenidate initiation.Aprevious study in-
vestigating the association between antidepressant medica-
tion and suicide also found the peak incidence of suicide
attempts to be immediately before initiationof an antidepres-
sant, suggesting that the attempt was a precipitant for initia-
tion of antidepressant treatment.45 Only 2 patients in our
sample diedwithin the studyperiod, andneither of themwas
receivingmethylphenidate treatmentat the timeofdeath.Fur-
thermore, the cause of death was not recorded as suicide.
Therefore, inourcohort,deathbysuicidewhile receivingmeth-
ylphenidate treatment is a rare outcome.
The suicidal ideation that precedes a suicide attemptmay
not be an acute event; patientswith suicidal ideationmaynot
carry out the attempt immediately.46 Therefore, theremaybe
a time lag between the beginning of suicidal ideation and the
suicideattemptevent.This lag couldpossibly contribute to the
increasedriskduringthefirst90daysofmethylphenidate treat-
ment (IRR, 3.91; 95% CI, 1.62-9.42).
To our knowledge, only 1 published report evaluated the
risk of suicidal behavior in patients receiving methylpheni-
date and/or other stimulant users. Chen et al21 identified an
increased risk of suicidal behavior inpatients receivingADHD
medications (hazard ratio [HR], 1.31; 95% CI, 1.19-1.44) com-
pared with nontreated patients with ADHD. Chen et al fur-
ther applied awithin-individualmethodology (ie, comparing
patient time with and without medication) and found no in-
creased risk of suicide-related events (HR,0.89; 95%CI, 0.79-
1.00). Among stimulant users, a reduced within-patient rate
of suicide-related events was seen during treatment periods
(HR, 0.81; 95% CI, 0.70-0.94). Chen et al assumed the risk of
suicidalbehavior tobeconstant innontreatmentperiods.How-
ever, in the present study, we found an increased risk of sui-
cide attempts before the initiation of treatment. This finding
suggests, therefore, that the estimate of risk derived by Chen
et al may need to be reevaluated.
Limitations
There are a number of limitations to our study. First, CDARS
does not have linkage to data from private medical practi-
tioners. However, in HK, the public sector is the main pro-
vider of specialist care47 and there are very few private child
and adolescent psychiatrists.18,48 As a consequence, the vast
majority of patients receiving methylphenidate are likely to
have been included in this study, and our sample should be
highly representative of the HK population. In addition, our
cohort included only clinically referred patients who had
sufficiently severe ADHD symptoms and/or impairment to
have received methylphenidate treatment. Therefore, our
cohort may have a higher baseline risk compared with non-
medicated patients. However, since we applied an SCCS
design, individual baseline risk does not affect our study
results and conclusion. Second, CDARS provides data on
drug prescriptions, but not on adherence, which may lead to
misclassification of exposure periods. Third, because we had
a comparatively long follow-up time, other time-varying
cofounding factors may affect the study results. Therefore,
we conducted various sensitivity analyses to explore the
potential effects of nonadherence and other confounding
factors, and the results were consistent.
Conclusions
The incidence of suicide attempts peaked before the start of
methylphenidate treatment, remained high immediately af-
ter the start ofmethylphenidate treatment, anddeclineddur-
ing continuationof treatment.Ourdata, therefore, donot sup-
port a causal associationbetweenmethylphenidate treatment
and suicide attempts.
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